Explore global clinical trial activity by specialty, country, phase, and therapeutic area. Create your ClinVio™ profile to be considered for adjudication, medical review, advisory, and specialist-support opportunities.
Live Trial Activity
Calculated from the trials currently indexed in ClinVio. Hover or focus any metric for its definition and source.
500
Total Trials Indexed
500
Currently Recruiting
14
Medical Specialties
67
Countries
50
Phase II Trials
27
Phase III Trials
+500
Added (30 days)
Live from ClinicalTrials.gov & EU Register
500 matching · 500 total indexed
Showing 1–12 of 500 matching trials
Tight ankle muscles can produce ankle equinus (limited ability to pull the foot upward) and occur often in children, significantly impacting their ability to walk. If not treated, children with ankle equinus frequently experience reduced function and long-term foot problems, such as pain. Currently, treatment options include surgery or Botulinum toxin (BoNTA) injection into the large calf muscles that point the foot downwards, aiming to reduce their tightness. However, these treatments can be less effective over time, can create prolonged calf weakness, and may require long-term bracing. Another small muscle in the leg, the plantaris, is believed to have some contribution to equinus in many children. It is sometimes included in treatment plans for equinus but its contribution is poorly understood. It is unclear whether targeting the plantaris alone could lead to better treatment of ankle equinus. Understanding the effect of treatments targeting the plantaris could help clinicians improve the management of ankle equinus. In this study, the investigators will look at the impact of surgical treatment to the plantaris in ankle equinus. The investigators hypothesize that the plantaris is a significant contributor to equinus. In this study, data will be collected from children undergoing surgical correction of ankle equinus, including lengthening of the plantaris and lengthening of the larger muscles producing equinus (the gastrocsoleus mechanism). Children will be randomly assigned to have either their plantaris or the gastrocsoleus lengthening be done first during surgery. All children will have both structures lengthened during surgery, only the order will be varied and all surgical procedures for each patient will be completed in a single setting. In both groups, maximum passive ankle dorsiflexion (upwards bend of the ankle with the knee straight) will be measured before and after each structure is lengthened. The outcome is maximum passive ankle dorsiflexion (upwards bend of the ankle) with the knee straight. The investigators expect that maximum passive ankle dorsiflexion will increase after lengthening of the plantaris. Understanding the contribution of the plantaris muscle in ankle equinus could lead to significant improvements in the treatment of children with tight ankles.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
Swallowing difficulties are extremely common and result in substantial morbidity, reduction in the quality of life, and mortality related to malnutrition and complications from regurgitation and aspiration. Unfortunately, our understanding regarding the pathophysiology of dysphagia and GERD has been hampered by focusing predominantly on circular muscle activity and ignoring the essential biomechanical properties of the esophageal wall that promote normal emptying. Our initial work explored the relationship between intrabolus pressure (IBP) and esophagogastric junction (EGJ) compliance as a metric for outflow resistance. This work highlighted the direct relationship between IBP and EGJ opening and was the foundation for the development of the classification scheme utilized around the world to diagnose esophageal motor disorders: "the Chicago Classification" (CC). Despite this improved understanding focused on bolus transit dynamics, there are still significant gaps in our scientific understanding centered on the lack of a true correlate for symptoms, reliable predictive models and effective treatments for Functional dysphagia, IEM and EGJOO. Given these limitations, we have developed novel approaches that combine assessments of primary and secondary peristalsis (a NeuroMyogenic Model of esophageal function). These will leverage our recent findings supporting the importance of the esophageal response to distension in bolus clearance, noting that this response of the esophageal wall to bolus retention or reflux is one of the most essential functions of the esophagus in preventing complications of aspiration, or reflux injury. We will also include an assessment of esophageal geometry and wall biomechanics (elasticity/dilatation) as these carry essential interactions with esophageal function that are overlooked in the current diagnostic paradigms. In order to test our hypothesis that wall mechanics are a major determinant of esophageal diseases, we had to develop new approaches and new technology to directly measure mechanical wall state, descending inhibition and LES opening. Using impedance techniques combined with manometry, we are now capable of assessing IBP and diameter changes across a space-time continuum (4D HRM). We also developed physics-based hybrid diagnostics that include a FLIP technique to assess esophageal work and power during volumetric distention (FLIP-MECH) and a fluoroscopy approach that simultaneously assesses esophageal diameter-pressure relationships (Fluoro-MECH). We also developed a new approach, Interactive FLIP Panometry, which facilitates an assessment of descending inhibition and the mechanism behind impaired LES opening. These tools will allow us to expand our models to combine an assessment of neuromyogenic function simultaneously with geometry. Our overarching goal will be to study well-defined patient populations (Functional Dysphagia, IEM/GERD, EGJOO and Achalasia) before and after targeted interventions to test the NeuroMyogenic and MechanoGeometric Model. This work will build upon the previous success of the CC and help advance the evolution of the CC by defining new, relevant biomechanical physiomarkers of disease activity that can identify new targets for therapeutic intervention and facilitate prediction of clinical outcomes.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
Alterations in the fibroblast growth factor receptor (FGFR) gene are involved in the development of cancer. These anomalies are found at very variable frequencies (from less than 1% to around 10%) in cancers of the bile ducts, bladder, uterus, brain, ovary, lung, airways, digestive tract, breast, etc. Pemigatinib is an anti-cancer drug that acts on cells with alterations in the FGFR gene. It is used in Europe to treat people with biliary tract cancer who carry a specific FGFR alteration. However, in various clinical trials, pemigatinib has shown interesting activity in a number of patients with different cancers presenting with an alteration in the FGFR gene. This treatment could therefore be effective in several types of cancer where an alteration in the FGFR gene is detected. The aim of this clinical trial is to learn if pemigatinib works to treat patients with recurrent and/or metastatic cancer (whatever the type of cancer excluding blood cancers and those already treated with pemigatinib) presenting an alteration in the FGFR gene. Patients will: * Take oral pemigatinig in 3-week cycles (every day for 2 weeks followed by one week without pemigatinib) as long as they benefit from it. * Visit the clinic once every 3 weeks for checkups and tests during the treatment period * Visit the clinic once every 3 months for checkups after stopping treatment for at least 12 months.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
The study evaluates the effect of anaesthetic agents to depth of anaesthesia. An improved PK-PD model wil be developed that will provide the basis for understanding the mechanisms, simulating various scenarios and developing algorithms for better and safer administration of anaesthetic agents.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
The goal of this observational study, is to improve the diagnostic assessment method of malnutrition and kidney diseases, amongst hospitalized and low priority patients, by evaluating modern methodology and biomarkers, with regards to an estimate of the nutritional status and kidney diseases, against current gold standards, and also investigate how body composition, hydration, inflammation and age affect the assessments.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
This prospective breast implant surveillance cohort will evaluate whether implant age, pocket plane, incision route, surface texture, and volume predict clinically significant capsular contracture. Women with Baker grade I or II aesthetic implants at enrollment will undergo standardized annual assessments for up to five years. The primary outcome is time to incident Baker grade III or IV contracture. Progression, pain, imaging, treatment, and patient-reported outcomes will also be described.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is designed using an adaptive approach. The number of the treated breasts will range between 250 and 530.
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
The goal of this observational study is to analyze the characteristics of left atrial electroanatomical maps in patients without a history of atrial fibrillation but with a high clinical risk of developing it, as indicated by the presence of structural heart disease or a CHA2DS2-VASc score ≥ 2 points. The study cohort will be compared to a historical cohort of patients with diagnosed atrial fibrillation in a propensity-matched fashion. The main questions it aims to answer are: * Are the left atrial electroanatomical changes a consequence or a precursor to the development of atrial fibrillation? * Are the left atrial electroanatomical findings different between patients with atrial fibrillation and those at high risk of developing it? * What is the prognostic impact of left atrial pathologic changes in patients without diagnosed atrial fibrillation in terms of cardiovascular outcomes?
Source: Verified clinical trial databases & partner networks· Updated Sep 10, 2026
Opportunities by Specialty
Live counts of indexed trials per specialty. Counts are calculated from current trial data, not projected.
How ClinVio Works
ClinVio is more than a trial listing — it is the path from interest to engagement.
Browse indexed trials by specialty, country, phase, and therapeutic area to see where specialist engagement is happening.
Add your specialization, experience, credentials, and availability. Takes only a few minutes.
ClinVio matches your profile to adjudication, review, advisory, and specialist-support opportunities.
Engage on flexible terms with sponsors and CROs, contribute your expertise, and receive compensation.
Why Doctors Join ClinVio
No guaranteed placements or income promises — just relevant opportunities and operational support.
Choose opportunities that fit your schedule — typically 10–40 hours per month, fully remote.
Engage with sponsors and CROs running trials across multiple countries and therapeutic areas.
Hourly, per-case, or monthly compensation models based on the type and duration of engagement.
Your professional information is encrypted in transit and accessed only with role-based permissions.
Receive notifications when new trials match your specialty, phase, and country preferences.
Our team supports onboarding, contracting, and ongoing engagement logistics end-to-end.
ClinVio helps sponsors, CROs, research organizations, and clinical trial teams discover relevant doctor profiles for adjudication, review, advisory, and specialist support roles.
Access a curated pool of verified specialists across multiple medical disciplines
Profiles pre-vetted for trial experience, qualifications, and availability
Source experts globally for single-site and multi-region trials
Purpose-built for adjudication, review, advisory, and oversight roles
Verified
Specialist Profiles
Pre-vetted for credentials, experience, and availability.
Global
Specialist Sourcing
Multiple countries and therapeutic areas.
4
Expert Role Types
Adjudication · Review · Advisory · Specialist Support
On Request
Profile Turnaround
Shortlist delivered after admin review of your request.
Trust, Privacy & Security
We describe our actual controls and plans accurately. We do not claim certifications or regulatory approvals that have not been completed.
All data in transit is encrypted using modern TLS standards.
Doctor profile data is only exposed to authorized sponsors after approval.
Profile sharing follows a staged disclosure model with consent tracking.
We follow privacy workflows intended to align with GDPR principles.
Profile views and key data access events are logged for accountability.
SOC 2 readiness planned · HIPAA applicability under review.
Compliance status: ClinVio does not claim HIPAA compliance, SOC 2 certification, FDA approval, or FDA compliance. HIPAA applicability is currently under review and SOC 2 readiness is planned. Regulatory alignments are described as design objectives, not completed certifications.
Create your professional profile in minutes and start receiving relevant clinical trial opportunity alerts.